PDT Partners LLC Grows Position in Boston Scientific Corporation $BSX

Key Points

• PDT Partners LLC significantly increased its stake in Boston Scientific Corporation by 541.1%, acquiring an additional 19,075 shares, bringing total holdings to 22,600 shares valued at approximately $2.28 million.
• Boston Scientific reported a quarterly earnings per share (EPS) of $0.75, surpassing analysts' expectations, with revenue for the quarter reaching $5.06 billion, marking a year-over-year increase of 22.8%.
• Analysts have a positive outlook on Boston Scientific, with a consensus rating of "Buy" and a price target of $117.50, alongside several firms upgrading their ratings in recent months.

PDT Partners LLC grew its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 541.1% in the first quarter, according to its most recent filing with the SEC. The fund owned 22,600 shares of the medical equipment provider's stock after acquiring an additional 19,075 shares during the period. PDT Partners LLC's holdings in Boston Scientific were worth $2,280,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. HM Payson & Co. lifted its stake in Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock valued at $694,000 after buying an additional 98 shares in the last quarter. Park Square Financial Group LLC raised its position in Boston Scientific by 5.2% during the first quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock valued at $208,000 after acquiring an additional 103 shares in the last quarter. HHM Wealth Advisors LLC raised its holdings in Boston Scientific by 13.2% during the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider's stock valued at $89,000 after buying an additional 103 shares in the last quarter. Forum Financial Management LP raised its holdings in Boston Scientific by 0.8% in the 1st quarter. Forum Financial Management LP now owns 13,448 shares of the medical equipment provider's stock worth $1,357,000 after acquiring an additional 112 shares during the period. Finally, Paladin Wealth LLC raised its stake in Boston Scientific by 1.6% during the 1st quarter. Paladin Wealth LLC now owns 7,156 shares of the medical equipment provider's stock valued at $722,000 after purchasing an additional 113 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the completion of the sale, the director directly owned 2,081 shares in the company, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock worth $18,397,457 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Trading Up 1.0%

Shares of BSX traded up $1.11 during trading hours on Monday, hitting $108.33. 3,195,618 shares of the stock were exchanged, compared to its average volume of 7,436,736. The business has a 50-day moving average of $104.77 and a 200-day moving average of $102.15. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $108.94. The firm has a market capitalization of $160.52 billion, a P/E ratio of 64.50, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period last year, the business posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

BSX has been the subject of a number of recent research reports. Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Citigroup reiterated a "buy" rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Leerink Partners started coverage on shares of Boston Scientific in a report on Monday, June 16th. They set an "outperform" rating and a $118.00 target price for the company. Morgan Stanley increased their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Finally, Barclays raised their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $117.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.